| 320.86 -0.34 (-0.11%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 376.59 |
1-year : | 439.86 |
| Resists | First : | 322.42 |
Second : | 376.59 |
| Pivot price | 318.83 |
|||
| Supports | First : | 318.65 |
Second : | 316.32 |
| MAs | MA(5) : | 320.63 |
MA(20) : | 318.93 |
| MA(100) : | 319.94  |
MA(250) : | 317.86 |
|
| MACD | MACD : | 0 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 79.8 |
D(3) : | 82.7 |
| RSI | RSI(14): 56.3 |
|||
| 52-week | High : | 362.41 | Low : | 221.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PEN ] has closed below upper band by 16.5%. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 322.81 - 324.51 | 324.51 - 325.95 |
| Low: | 316.05 - 318.01 | 318.01 - 319.68 |
| Close: | 317.66 - 320.97 | 320.97 - 323.78 |
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Sat, 17 Oct 2026
Penumbra stock has November 4 earnings date with USD 401.41 million forecast - ad-hoc-news.de
Mon, 12 Oct 2026
Penumbra, Inc. (PEN) Stock Forecasts - Yahoo Finance
Tue, 06 Oct 2026
In a lung-clot study, fitness-watch steps lined up with clinic walking tests - Stock Titan
Wed, 16 Sep 2026
Reasons to Retain Penumbra Stock in Your Portfolio for Now - Yahoo Finance
Mon, 07 Sep 2026
Price to earnings forward of Penumbra, Inc. – NYSE:PEN - TradingView
Thu, 30 Jul 2026
Penumbra, Inc. Reports Second Quarter 2026 Financial Results - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 39 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 88.3 (%) |
| Shares Short | 2,250 (K) |
| Shares Short P.Month | 1,730 (K) |
| EPS | 4.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 38.86 |
| Profit Margin | 10.6 % |
| Operating Margin | 10.5 % |
| Return on Assets (ttm) | 6.4 % |
| Return on Equity (ttm) | 11.3 % |
| Qtrly Rev. Growth | 14.8 % |
| Gross Profit (p.s.) | 25.89 |
| Sales Per Share | 38.08 |
| EBITDA (p.s.) | 5.18 |
| Qtrly Earnings Growth | -23.5 % |
| Operating Cash Flow | 278 (M) |
| Levered Free Cash Flow | 161 (M) |
| PE Ratio | 78.83 |
| PEG Ratio | 3.5 |
| Price to Book value | 8.25 |
| Price to Sales | 8.42 |
| Price to Cash Flow | 45.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|